Company: Pfizer Inc.
Ticker: PFE
Form: 10-K
Filed: 2026-02-26
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Pfizer Inc.'s total assets in fiscal year 2025?
Question Type: value_lookup

Concept: Assets
Answer (Numeric): 208160.0
Answer (Display): $208,160 million
Unit: USD millions

Evidence:
[{"chunk_id": "212", "equivalent_chunk_ids": ["212"], "section": "Consolidated Balance Sheets", "supports": ["main"], "text": "Pfizer Inc. and Subsidiary Companies\nAs of December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\nAssets\nCash and cash equivalents\n1,142\n1,043\nShort-term investments\n12,454\n19,434\nTrade accounts receivable, net of allowance for doubtful accounts: 2025—$\n; 2024—$\n11,874\n11,463\nInventories\n10,654\n10,851\nCurrent tax assets\n3,967\n3,314\nOther current assets\n2,808\n4,253\nTotal current assets\n42,898\n50,358\nLong-term investments\n1,621\n2,228\nProperty, plant and equipment, net\n19,317\n18,393\nIdentifiable intangible assets, net\n53,731\n55,411\nGoodwill\n71,264\n68,527\nNoncurrent deferred tax assets and other noncurrent tax assets\n9,699\n8,662\nOther noncurrent assets\n9,631\n9,817\nTotal assets\n208,160\n213,396\nLiabilities and Equity\nShort-term borrowings, including current portion of long-term debt: 2025—$\n2,997\n; 2024—$\n3,747\n3,154\n6,946\nTrade accounts payable\n5,240\n5,633\nDividends payable\n2,445\n2,437\nIncome taxes payable\n3,103\n2,910\nAccrued compensation and related items\n3,610\n3,838\nDeferred revenues\n1,511\nOther current liabilities\n18,648\n19,720\nTotal current liabilities\n36,984\n42,995\nLong-term debt\n61,641\n57,405\nPension and postretirement benefit obligations\n2,041\n2,115\nNoncurrent deferred tax liabilities\n2,401\n2,122\nOther taxes payable\n3,591\n6,112\nOther noncurrent liabilities\n14,725\n14,150\nTotal liabilities\n121,385\n124,899\nCommitments and Contingencies\nCommon stock, $\n0.05\npar value;\n12,000\nshares authorized; issued: 2025—\n9,621\n; 2024—\n9,593\nAdditional paid-in capital\n94,469\n93,603\nTreasury stock, shares at cost: 2025—\n3,935\n; 2024—\n3,926\n115,015\n114,763\nRetained earnings\n114,610\n116,725\nAccumulated other comprehensive loss\n8,069\n7,842\nTotal Pfizer Inc. shareholders’ equity\n86,476\n88,203\nEquity attributable to noncontrolling interests\nTotal equity\n86,775\n88,497\nTotal liabilities and equity\n208,160\n213,396\nSee Accompanying Notes.\nPfizer Inc.\n2025 Form 10-K"}]

Derivation: